Check out the new Stock Movers Podcast from Bloomberg. Subscribe for five-minute episodes on today's winners and losers in the stock market.   

Listen on Apple:https://apple.co/4kJ43ON   
Listen on Spotify:https://tinyurl.com/mr385jv6   
Listen on other platforms:https://link.podtrac.com/h0zn7xir

Check out the new <a href="https://link.podtrac.com/h0zn7xir" data-destination="https://link.podtrac.com/h0zn7xir">Stock Movers Podcast</a> from Bloomberg. Subscribe for five-minute episodes on today's winners and losers in the stock market.&nbsp; &nbsp; <a data-destination="rte:bind"></a><a href="https://apple.co/4kJ43ON" data-destination="https://apple.co/4kJ43ON">Listen on Apple:</a> <a href="https://apple.co/4kJ43ON">https://apple.co/4kJ43ON</a>&nbsp; &nbsp; <a href="https://tinyurl.com/mr385jv6" data-destination="https://tinyurl.com/mr385jv6">Listen on Spotify:</a> <a href="https://tinyurl.com/mr385jv6">https://tinyurl.com/mr385jv6</a>&nbsp; &nbsp; <a data-destination="rte:bind"></a><a href="https://link.podtrac.com/h0zn7xir" data-destination="https://link.podtrac.com/h0zn7xir">Listen on other platforms:</a> <a href="https://link.podtrac.com/h0zn7xir">https://link.podtrac.com/h0zn7xir</a>

Listen for investment news and in-depth company research. 

Hosts Paul Sweeney and Scarlet Fu harness the power of Bloomberg Intelligence to analyze investments on Wall Street. Watch Bloomberg Intelligence LIVE on YouTube, weekdays from 10AM to 12PM ET: http://bit.ly/3vTiACF.

Listen for investment news and in-depth company research. Hosts Paul Sweeney and Scarlet Fu harness the power of Bloomberg Intelligence to analyze investments on Wall Street. Watch Bloomberg Intelligence LIVE on YouTube, weekdays from 10AM to 12PM ET: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.

Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze markets, companies and industries.

Bloomberg Intelligence

Introducing: Stock Movers Podcast

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/fc79f03e-1aa9-466e-b2b2-b2ba00c1aebc/transcript

Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF.

Bloomberg Intelligence hosted by Paul Sweeney and Judy Lagrou

- Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals Analyst, discusses the latest in the biotech sector. A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer. The trial met its main goal as the vaccine, combined with Merck’s immune drug Keytruda, prevented the cancer’s return after it was surgically removed more often than the immunotherapy alone.

-Deborah Aitken, Bloomberg Intelligence Luxury Goods Analyst, discusses Estee Lauder earnings. Estée Lauder Cos. shares jumped after its results beat estimates and ended a run of three straight declines in annual revenue. The company reported revenue of $3.6 billion in its fiscal fourth quarter and adjusted earnings per share of $0.39, which topped expectations.

-Craig Trudell, Bloomberg Managing Editor of Global Business Coverage, discusses Target earnings. Target Corp. lifted its full-year guidance after results outpaced estimates in the latest quarter, suggesting the big-box retailer may be moving past a lengthy sales slump. The company now expects net sales to increase about 5% in the current fiscal year and raised its adjusted earnings target after second-quarter sales surpassed analyst estimates.

-Lindsay Dutch, Bloomberg Intelligence Consumer Hardlines Senior Analyst, discusses Lowe’s earnings. Lowe’s Cos. cut its outlook for the full year after posting results that missed Wall Street estimates, showing how a stubbornly weak housing market is eroding the home-improvement retailer’s performance.  The company now expects comparable sales to be flat this fiscal year, after previously forecasting as much as 2% growth. Comparable sales, which measure results at locations open at least a year, grew 0.2% in the second quarter, missing the average of estimates compiled by Bloomberg. 

Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF.
Bloomberg Intelligence hosted by Paul Sweeney and Judy Lagrou - Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals Analyst, discusses the latest in the biotech sector. A personalized vaccine developed by Moderna Inc. and Merck &amp; Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer. The trial met its main goal as the vaccine, combined with Merck&rsquo;s immune drug Keytruda, prevented the cancer&rsquo;s return after it was surgically removed more often than the immunotherapy alone. -Deborah Aitken, Bloomberg Intelligence Luxury Goods Analyst, discusses Estee Lauder earnings. Est&eacute;e Lauder Cos. shares jumped after its results beat estimates and ended a run of three straight declines in annual revenue. The company reported revenue of $3.6 billion in its fiscal fourth quarter and adjusted earnings per share of $0.39, which topped expectations. -Craig Trudell, Bloomberg Managing Editor of Global Business Coverage, discusses Target earnings. Target Corp. lifted its full-year guidance after results outpaced estimates in the latest quarter, suggesting the big-box retailer may be moving past a lengthy sales slump. The company now expects net sales to increase about 5% in the current fiscal year and raised its adjusted earnings target after second-quarter sales surpassed analyst estimates. -Lindsay Dutch, Bloomberg Intelligence Consumer Hardlines Senior Analyst, discusses Lowe&rsquo;s earnings. Lowe&rsquo;s Cos.&nbsp;cut its outlook for the full year after posting results that missed Wall Street estimates, showing how a stubbornly weak housing market is eroding the home-improvement retailer&rsquo;s performance.&nbsp; The company now expects comparable sales to be flat this fiscal year, after previously forecasting as much as 2% growth. Comparable sales, which measure results at locations open at least a year, grew 0.2% in the second quarter, missing the average of estimates compiled by Bloomberg.&nbsp;

Moderna and Merck Revive mRNA Hopes With Melanoma Success

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/1f6949c8-33e4-4b20-b0e5-b4ab011529bb/transcript

Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF.

Bloomberg Intelligence hosted by Paul Sweeney and Scarlet Fu 

-David Kirkpatrick, Founder of Techonomy, discusses the Meta youth social media addiction trial. Meta Platforms Inc. is facing a jury trial in federal court over claims that it deliberately designed Facebook and Instagram to encourage compulsive use among young users. The top legal officers of 29 states are seeking financial penalties and court orders that could force Meta to change how it operates its platforms, alleging violations of state consumer protection and federal privacy laws.

-Mandeep Singh, Global Head of Tech Research for Bloomberg Intelligence, discusses top tech stories. Anthropic PBC is on track to generate annualized revenue of more than $65 billion based on its current performance, up more than sevenfold from its pace at the end of last year.

-- Lindsay Dutch, Bloomberg Intelligence Consumer Hardlines Senior Analyst, discusses Home Depot earnings. Home Depot Inc.’s results beat estimates in the latest quarter, a sign that spending on improvement projects is holding up despite high borrowing and housing costs. The company’s strategy, which includes expanding its business serving professional contractors and building out its e-commerce offerings, has helped to blunt the impact of a housing market weighed down by high home prices and interest rates.

-Tim Craighead, Bloomberg Intelligence Global Chief Content Officer, discusses ten companies to watch in the APAC region. Bloomberg Intelligence analysts have identified the most interesting names from their group of high-confidence Focus Ideas. Spanning sectors and regions, each scenario outlines a catalyst in the next few months that supports BI’s case.

 

Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF.
Bloomberg Intelligence hosted by Paul Sweeney and Scarlet Fu -David Kirkpatrick, Founder of Techonomy, discusses the Meta youth social media addiction trial. Meta Platforms Inc. is facing a jury trial in federal court over claims that it deliberately designed Facebook and Instagram to encourage compulsive use among young users. The top legal officers of 29 states are seeking financial penalties and court orders that could force Meta to change how it operates its platforms, alleging violations of state consumer protection and federal privacy laws. -Mandeep Singh, Global Head of Tech Research for Bloomberg Intelligence, discusses top tech stories. Anthropic PBC is on track to generate annualized revenue of more than $65 billion based on its current performance, up more than sevenfold from its pace at the end of last year. -- Lindsay Dutch, Bloomberg Intelligence Consumer Hardlines Senior Analyst, discusses Home Depot earnings. Home Depot Inc.&rsquo;s results beat estimates in the latest quarter, a sign that spending on improvement projects is holding up despite high borrowing and housing costs. The company&rsquo;s strategy, which includes expanding its business serving professional contractors and building out its e-commerce offerings, has helped to blunt the impact of a housing market weighed down by high home prices and interest rates. -Tim Craighead, Bloomberg Intelligence Global Chief Content Officer, discusses ten companies to watch in the APAC region. Bloomberg Intelligence analysts have identified the most interesting names from their group of high-confidence Focus Ideas. Spanning sectors and regions, each scenario outlines a catalyst in the next few months that supports BI&rsquo;s case.
&nbsp;

Meta Sees Trillion-Dollar Threat in Social Media Trial 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/9f9f7ffa-ae68-4fd2-b37f-b4aa011690e1/transcript

Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF.

Bloomberg Intelligence hosted by Paul Sweeney and Stacey Vanek Smith

-Yiqin Shen, Bloomberg Equities Reporter, discusses 13F filings. Investment firms for ultra-wealthy individuals have built up billions of dollars of exposure to SpaceX, highlighting their ability to muscle in on sought-after business opportunities. More than a dozen family offices held a total of at least $3.8 billion in SpaceX through the first half of 2026, according to US filings.

-Ed Ludlow, Bloomberg Tech Anchor, discusses top tech stories. Alphabet Inc. is looking to raise about A$5 billion in its debut bond offering in Australia, as US tech firms raise debt to fuel AI spending.
Separately, AI-linked stocks rose after Anthropic PBC told prospective investors that its preliminary second quarter revenue was $11.5 billion, an at least 14-fold increase versus the same period a year ago.

-Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals Analyst, discusses the latest in the biotech sector. AstraZeneca Plc is stopping a clinical trial of the experimental drug volrustomig as it didn’t look set to help fight lung cancer better than existing therapies. The company had two separate late-stage trial successes that strengthen key cancer franchises, including one where patients with non-small cell lung cancer received Tagrisso in combination with Orpathys.

-Sridhar Natarajan, Bloomberg News Chief Wall Street Correspondent, discusses the Bloomberg Big Take story: “Big Take: ‘I Hate Losing’: Walter Rushes Makeover as DOJ Probes His Empire.” Description: The CEO of Guggenheim Partners and owner of the LA Dodgers flipped the Lakers within a year and has explored other steps to pay down loans from his insurers.

Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF.
Bloomberg Intelligence hosted by Paul Sweeney and Stacey Vanek Smith -Yiqin Shen, Bloomberg Equities Reporter, discusses 13F filings. Investment firms for ultra-wealthy individuals have built up billions of dollars of exposure to SpaceX, highlighting their ability to muscle in on sought-after business opportunities. More than a dozen family offices held a total of at least $3.8 billion in SpaceX through the first half of 2026, according to US filings. -Ed Ludlow, Bloomberg Tech Anchor, discusses top tech stories. Alphabet Inc. is looking to raise about A$5 billion in its debut bond offering in Australia, as US tech firms raise debt to fuel AI spending. Separately, AI-linked stocks rose after&nbsp;Anthropic PBC&nbsp;told prospective investors that its preliminary second quarter revenue was $11.5 billion, an at least 14-fold increase versus the same period a year ago. -Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals Analyst, discusses the latest in the biotech sector. AstraZeneca Plc is stopping a clinical trial of the experimental drug volrustomig as it didn&rsquo;t look set to help fight lung cancer better than existing therapies. The company had two separate late-stage trial successes that strengthen key cancer franchises, including one where patients with non-small cell lung cancer received Tagrisso in combination with Orpathys. -Sridhar Natarajan, Bloomberg News Chief Wall Street Correspondent, discusses the Bloomberg Big Take story: &ldquo;Big Take: &lsquo;I Hate Losing&rsquo;: Walter Rushes Makeover as DOJ Probes His Empire.&rdquo; Description: The CEO of Guggenheim Partners and owner of the LA Dodgers flipped the Lakers within a year and has explored other steps to pay down loans from his insurers.

Family Offices Amass $3.8 Billion SpaceX Bet in Boost for Musk 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/1f0810f8-5f8e-4839-adf1-b4a90111c8cb/transcript

Introducing: Stock Movers Podcast

In 1 playlist(s)

Bloomberg Intelligence

Social links

Follow podcast

Recent clips